| An SI Board Since August 2011 |
| Posts |
SubjectMarks |
Bans |
Symbol |
| 0 |
2 |
0
|
PDLI |
|
PDL BioPharma, Inc. (PDL) is engaged in the management of its antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with pharmaceutical and biotechnology companies. The Company receives royalties based on these license agreements on sales of a number of humanized antibody products marketed and also may receive royalty payments on additional humanized antibody products launched before final patent expiry in December 2014. The Company has entered into licensing agreements with numerous entities that are independently developing or have developed humanized antibodies pursuant to which it has licensed certain rights under its Queen et al. patents to make, use, sell, offer for sale and import humanized antibodies. It receives royalties on net sales of products that are made, used or sold prior to patent expiry. In general, these agreements cover antibodies targeting antigens specified in the license agreements.
PDL BioPharma Inc (NASDAQ:PDLI) is a member of the Russell 3000, giving it special status as one of the largest 3000 companies on the U.S. stock markets.
Does anyone have thoughts on this stock, and its future performance?
FDiCianni
|
|
|
